Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2022-06-16 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于召开2022年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2022 second extraordinary general meeting (临时股东大会) of Tianjin Ruipu Biotechnology Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures, registration methods, and proxy forms. The document does not contain financial statements or results but is focused on informing shareholders about the meeting and the proposals to be voted on. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document length is 4343 characters, which is sufficient for detailed meeting materials rather than a brief announcement. Therefore, the correct classification is PSI with high confidence.
2022-06-16 Chinese
北京市康达律师事务所关于天津瑞普生物技术股份有限公司2019年限制性股票激励计划第三个解除限售期解除限售条件成就及回购注销部分限制性股票相关事项的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2019 restricted stock incentive plan of Tianjin Ruipu Biotechnology Co., Ltd. It discusses the achievement of the third release period conditions for restricted stock and the repurchase and cancellation of some restricted stocks. The document includes detailed legal analysis, references to company board and shareholder meetings, approval processes, and compliance with relevant laws and regulations. It is not a financial report, earnings release, or a general announcement but a specialized legal opinion related to stock incentive plans and corporate governance matters. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal opinion and compliance document rather than a financial report or management announcement.
2022-06-16 Chinese
上海荣正投资咨询股份有限公司关于天津瑞普生物技术股份有限公司2019年限制性股票激励计划第三期解除限售条件成就之独立财务顾问意见
Capital/Financing Update Classification · 95% confidence The document is an independent financial advisor's opinion report regarding the achievement of the third phase of lifting restrictions on restricted stock under the 2019 restricted stock incentive plan of Tianjin Ruipu Biotechnology Co., Ltd. It includes detailed explanations of the stock incentive plan, approval procedures, performance conditions, and the number of shares eligible for lifting restrictions. The document is not a general annual or quarterly financial report, nor is it a simple announcement or certification. It is a specialized advisory report related to stock incentive plans and their conditions. This type of document fits best under the category of Capital/Financing Update (CAP), as it deals with stock incentive plans and related equity capital matters.
2022-06-16 Chinese
独立董事对第四届董事会第四十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various corporate governance matters discussed at a board meeting, including stock incentive plans, share repurchase and cancellation, amendments to the company charter, and guarantees for subsidiaries. It references compliance with stock exchange listing rules and company articles of association. The content focuses on board-level decisions and approvals rather than financial results or audit findings. There is no presentation of financial statements or detailed financial data. The document is not a full annual or interim report, nor an earnings release or audit report. It is not a regulatory filing or announcement of a report publication. The document fits best as Board/Management Information (MANG) because it relates to board meeting decisions and independent directors' opinions on corporate governance matters.
2022-06-16 Chinese
关于公司及子公司继续开展资产池业务并提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Tianjin Ruipu Biological Technology Co., Ltd. regarding the continuation of asset pool business and provision of guarantees by the company and its subsidiaries. It includes comprehensive information about the business overview, cooperating banks, business terms, risk control measures, guarantee details, financial data of the company and subsidiaries, board opinions, independent directors' opinions, supervisory board opinions, and cumulative guarantee amounts. The document is regulatory in nature, disclosing a corporate financing and guarantee arrangement, but it is not a full financial report, earnings release, or management discussion. It is not a simple announcement of a report publication but a substantive disclosure about financing activities and guarantees. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8140 characters) and detailed content support this classification with high confidence.
2022-06-16 Chinese
关于回购注销2019年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the repurchase and cancellation of restricted shares under the 2019 restricted stock incentive plan. It details the board and supervisory approvals, the reasons for repurchase (employee departure and performance issues), the number of shares repurchased and cancelled, pricing adjustments, and legal opinions. The document is a formal disclosure about a share repurchase related to an equity incentive plan, including changes in share capital structure. It is not a full financial report, earnings release, or management discussion, but a specific announcement about share repurchase and cancellation. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2022-06-16 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.